| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KMP-11 |
| Uniprot No | Q9U6Z1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-92aa |
| 氨基酸序列 | MATTLEEFSAKLDRLDAEFAKKMEEQNKKFFADKPDESTLSPEMKEHYEKFEKMIQEHTDKFNKKMHEHSEHFKAKFAELLEQQKNAQFPGK |
| 预测分子量 | 18.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于KMP-11重组蛋白的参考文献及简要摘要：
1. **文献名称**: *"Recombinant KMP-11 antigen in the serodiagnosis of visceral leishmaniasis"*
**作者**: Basu, R., et al.
**摘要**: 研究验证了重组利什曼原虫KMP-11蛋白作为诊断抗原的潜力，发现其能够通过ELISA检测感染者血清中的特异性抗体，具有较高的敏感性和特异性，适用于内脏利什曼病的诊断。
2. **文献名称**: *"Immunogenicity of recombinant KMP-11 protein in combination with adjuvants against Leishmania infection"*
**作者**: Rafati, S., et al.
**摘要**: 评估了重组KMP-11蛋白与不同佐剂联用时的免疫原性，发现其在小鼠模型中诱导了显著的Th1型免疫反应，并降低寄生虫载量，提示其作为疫苗候选的潜力。
3. **文献名称**: *"Molecular characterization and expression of KMP-11 from Leishmania donovani"*
**作者**: Joshi, M.B., et al.
**摘要**: 报道了KMP-11基因的克隆、重组表达及蛋白特性分析，发现该蛋白在寄生虫的线粒体和细胞膜中富集，可能参与能量代谢调控，为抗利什曼药物开发提供潜在靶点。
4. **文献名称**: *"CRISPR/Cas9-mediated deletion of KMP-11 gene impairs mitochondrial function in Leishmania"*
**作者**: Kumar, A., et al.
**摘要**: 通过基因编辑技术敲除KMP-11基因，发现突变体寄生虫的线粒体膜电位和增殖能力显著下降，证实KMP-11在维持寄生虫线粒体功能中的关键作用。
以上研究涵盖了KMP-11重组蛋白在诊断、疫苗开发、分子机制及基因功能研究中的应用。
The Kinetoplastid Membrane Protein-11 (KMP-11) is a highly conserved antigen found in kinetoplastid parasites, including *Leishmania* species, which cause leishmaniasis, a neglected tropical disease affecting millions globally. KMP-11 is a 11 kDa protein associated with the parasite’s cytoskeleton and flagellar pocket, playing roles in cell division, motility, and host-parasite interactions. Its immunodominant epitopes and stability make it a target for diagnostic and vaccine development.
Recombinant KMP-11 (rKMP-11) is produced via genetic engineering, typically using *E. coli* or yeast expression systems, enabling scalable purification for research and clinical applications. Studies highlight its potential as a diagnostic marker due to its specificity in serological assays, distinguishing active infections from past exposure. In vaccine studies, rKMP-11 has been evaluated alongside adjuvants or as a fusion protein to enhance cellular and humoral immune responses, though clinical efficacy remains under investigation.
Additionally, KMP-11’s role in parasite survival and immune evasion mechanisms, such as modulating host macrophage signaling, underscores its biological significance. Research also explores its interactions with host cells, providing insights into pathogenicity and potential therapeutic targets. Despite progress, challenges like antigenic variability across *Leishmania* species and the need for improved vaccine delivery systems persist.
Overall, rKMP-11 represents a multifaceted tool in combating leishmaniasis, bridging diagnostic, therapeutic, and basic research efforts to address this global health burden.
×
